pembrolizumab,eftilagimod
merck,novartis
['eftilagimod', 'tacti-002', 'pembro', 'thank you', 'head and neck']
thank you, for discussing final results from tacti-002 part c of eftilagimod alpha and pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma, live at the annual meeting. to hear more, check back here: #asco23 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.